Suven Life secures product patent in S Korea, US
13 October 2014
Hyderabad-based Suven Life Sciences today said that it has been granted one product patent from US regulator and South Korea corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2030.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven said it has 19 patents in the US and 15 in South Korea.
"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts," Suven said in a statement.
Products out of these inventions can be out-licensed at various phases of clinical development like at Phase-I or Phase-II, it added.
According to Suven, its drug discovery portfolio which encompasses several new therapeutic areas, such as major depressive disorder (MDD), obesity and pain through neuronal nicotinic receptor modulators.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for major depressive disorder (MDD) with high unmet medical need with huge market potential globally'' said Venkat Jasti, CEO, Suven Life Science.
Suven is a biopharmaceutical company with 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.